600380 健康元
已收盘 05-15 15:00:00
资讯
新帖
简况
每周股票复盘：健康元（600380）获新药临床试验批准
证券之星 · 05-10
每周股票复盘：健康元（600380）获新药临床试验批准
健康元（600380）披露获得药物临床试验批准通知书，5月6日股价下跌0.82%
证券之星 · 05-06
健康元（600380）披露获得药物临床试验批准通知书，5月6日股价下跌0.82%
健康元(600380.SH)获得药物临床试验批准通知书
智通财经 · 05-06
健康元(600380.SH)获得药物临床试验批准通知书
每周股票复盘：健康元（600380）呼吸制剂结构优化创新药占比超35%
证券之星 · 05-02
每周股票复盘：健康元（600380）呼吸制剂结构优化创新药占比超35%
股市必读：健康元（600380）4月29日披露最新机构调研信息
证券之星 · 04-30
股市必读：健康元（600380）4月29日披露最新机构调研信息
股市必读：健康元一季报 - 第一季度单季净利润同比下降4.78%
中金财经 · 04-27
股市必读：健康元一季报 - 第一季度单季净利润同比下降4.78%
每周股票复盘：健康元（600380）Q1净利降4.78%，股东户数减少2507户
证券之星 · 04-26
每周股票复盘：健康元（600380）Q1净利降4.78%，股东户数减少2507户
告别乙流多次服药！健康元创新药玛帕西沙韦胶囊或成更优选择
中金财经 · 04-25
告别乙流多次服药！健康元创新药玛帕西沙韦胶囊或成更优选择
健康元(600380.SH)发布一季度业绩，归母净利润4.15亿元，同比下降4.78%
智通财经 · 04-24
健康元(600380.SH)发布一季度业绩，归母净利润4.15亿元，同比下降4.78%
图解健康元一季报：第一季度单季净利润同比下降4.78%
证券之星 · 04-24
图解健康元一季报：第一季度单季净利润同比下降4.78%
健康元(600380)3月31日股东户数7.6万户，较上期减少3.19%
中金财经 · 04-24
健康元(600380)3月31日股东户数7.6万户，较上期减少3.19%
健康元最新公告：控股子公司JP-1366片获临床试验批准
证券之星 · 04-10
健康元最新公告：控股子公司JP-1366片获临床试验批准
健康元(600380.SH)：TSLP单抗新增适应症获得药物临床试验批准通知书
智通财经 · 04-07
健康元(600380.SH)：TSLP单抗新增适应症获得药物临床试验批准通知书
健康元（600380）披露2025年年度报告，4月3日股价下跌1.57%
证券之星 · 04-03
健康元（600380）披露2025年年度报告，4月3日股价下跌1.57%
健康元(600380)3月31日股东户数7.66万户，较上期减少2.47%
证券之星 · 04-01
健康元(600380)3月31日股东户数7.66万户，较上期减少2.47%
健康元(600380.SH)发布2025年度业绩，归母净利润13.36亿元，同比下降3.68%
智通财经 · 03-31
健康元(600380.SH)发布2025年度业绩，归母净利润13.36亿元，同比下降3.68%
每周股票复盘：健康元（600380）获两项药物临床试验批件
证券之星 · 03-29
每周股票复盘：健康元（600380）获两项药物临床试验批件
健康元最新公告：新一代糖皮质激素获得药物临床试验批准通知书
证券之星 · 03-26
健康元最新公告：新一代糖皮质激素获得药物临床试验批准通知书
健康元最新公告：注射用布瑞哌唑微球获临床试验批准
证券之星 · 03-26
健康元最新公告：注射用布瑞哌唑微球获临床试验批准
股市必读：健康元（600380）3月23日收盘跌5.2%，主力净流入601.31万元
证券之星 · 03-24
股市必读：健康元（600380）3月23日收盘跌5.2%，主力净流入601.31万元
加载更多
公司概况
公司名称：
健康元药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2001-06-08
主营业务：
健康元药业集团股份有限公司的主营业务是医药产品及保健品研发、生产及销售。公司的主要产品是化学制剂、化学原料药及中间体、中药制剂、诊断试剂及设备、保健食品、生物制品。
发行价格：
24.80
{"stockData":{"symbol":"600380","market":"SH","secType":"STK","nameCN":"健康元","latestPrice":10.49,"timestamp":1778828401000,"preClose":10.67,"halted":0,"volume":17296385,"delay":0,"changeRate":-0.0169,"floatShares":1829000000,"shares":1829000000,"eps":0.7187,"marketStatus":"已收盘","change":-0.18,"latestTime":"05-15 15:00:00","open":10.66,"high":10.72,"low":10.44,"amount":183000000,"amplitude":0.0262,"askPrice":10.49,"askSize":53,"bidPrice":10.48,"bidSize":24,"shortable":0,"etf":0,"ttmEps":0.7187,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":5,"adr":0,"adjPreClose":10.67,"symbolType":"stock","openAndCloseTimeList":[[1778808600000,1778815800000],[1778821200000,1778828400000]],"highLimit":11.74,"lowLimit":9.6,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1829453386,"isCdr":false,"pbRate":1.23,"roa":"--","peRate":14.595798,"roe":"2.7%","epsLYR":0.73,"committee":0.910573,"marketValue":19191000000,"turnoverRate":0.0095,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-05-18。","floatMarketCap":19191000000},"requestUrl":"/m/hq/s/600380","defaultTab":"news","newsList":[{"id":"2634125524","title":"每周股票复盘：健康元（600380）获新药临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2634125524","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634125524?lang=zh_cn&edition=full","pubTime":"2026-05-10 03:14","pubTimestamp":1778354052,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，健康元报收于10.76元，较上周的10.93元下跌1.56%。本周关注点公司公告汇总：健康元获注射用JKN2501药物临床试验批准，用于治疗HAP/VAP。药物后续仍需临床试验及审评审批，存在不确定性。健康元药业集团股份有限公司于近日收到证券事务代表罗逍女士的辞职报告，因个人原因申请辞去公司证券事务代表职务。本次担保已有反担保安排，健康元按持股比例提供26.84%的反担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000001274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600380","BK0188","BK0046","BK0239","BK0114","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633132500","title":"健康元（600380）披露获得药物临床试验批准通知书，5月6日股价下跌0.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633132500","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633132500?lang=zh_cn&edition=full","pubTime":"2026-05-06 23:02","pubTimestamp":1778079757,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，健康元报收于10.84元，较前一交易日下跌0.82%，最新总市值为198.31亿元。该股当日开盘10.93元，最高11.01元，最低10.82元，成交额达1.89亿元，换手率为0.95%。此前该药品已获批用于复杂性尿路感染的临床试验，正在开展I期临床试验。截至公告日，累计研发投入约1470.43万元。药物后续仍需临床试验及审评审批，存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600040362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600380","BK0028","BK0188","BK0114","BK0046","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633189307","title":"健康元(600380.SH)获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2633189307","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633189307?lang=zh_cn&edition=full","pubTime":"2026-05-06 18:20","pubTimestamp":1778062815,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健康元(600380.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司申报的新型β-内酰胺酶抑制剂开展临床试验。根据《中华人民共和国药品管理法》及有关规定，经审查，2026年2月12日受理的注射用JKN2501临床试验申请符合药品注册的有关要求，同意本品开展拟与美罗培南联用，用于治疗革兰氏阴性菌或革兰氏阳性菌引起的医院获得性肺炎和呼吸机相关性肺炎(HAP/VAP)的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438625.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","BK0046","BK0188","600380","BK0077","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632695642","title":"每周股票复盘：健康元（600380）呼吸制剂结构优化创新药占比超35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632695642","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632695642?lang=zh_cn&edition=full","pubTime":"2026-05-02 03:48","pubTimestamp":1777664893,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，健康元报收于10.93元，较上周的10.83元上涨0.92%。健康元当前最新总市值199.96亿元，在化学制药板块市值排名24/150，在两市A股市值排名1080/5200。来自机构调研要点：保健品业务2025年同比增长超过37%，延续高增长态势。但呼吸板块呈现结构优化趋势，妥布霉素吸入溶液保持快速增长，创新药占呼吸板块收入比例已提升至35%以上，转型战略成效显现。保健品业务2025年同比增长超37%，保持强劲增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1161","BK0239","BK1574","BK0188","159992","BK0077","BK0028","BK0046","BK0114","600380"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631547542","title":"股市必读：健康元（600380）4月29日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2631547542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631547542?lang=zh_cn&edition=full","pubTime":"2026-04-30 01:29","pubTimestamp":1777483752,"startTime":"0","endTime":"0","summary":"截至2026年4月29日收盘，健康元报收于11.1元，上涨2.02%，换手率1.03%，成交量18.8万手，成交额2.08亿元。机构调研要点今年一季度受流感发病水平季节性回落影响，呼吸道用药需求出现波动，对公司呼吸制剂销售造成短期影响。截至公告日，要约期间已结束，LIAN SGP将持有IMP 104,545,781股股份，占其注册资本及有表决权股份的67.87%和67.88%。目前将推进价款支付及股份交割程序。本次交易尚受市场变化及审批因素影响，存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000004782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0077","BK0239","600380","BK0188","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630353270","title":"股市必读：健康元一季报 - 第一季度单季净利润同比下降4.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630353270","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630353270?lang=zh_cn&edition=full","pubTime":"2026-04-27 10:11","pubTimestamp":1777255883,"startTime":"0","endTime":"0","summary":"来自股本股东变化：截至2026年3月31日，公司股东户数环比下降3.19%至7.6万户，户均持股上升至2.41万股。来自业绩披露要点：2026年一季度公司主营收入同比下降8.99%，归母净利润同比下降4.78%。 健康元2026年第一季度实现营业收入3,721,497,528.96元，同比下降8.99%；归属于上市公司股东的净利润为414,971,222.32元，同比下降4.78%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260427/32178670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["600380"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630807047","title":"每周股票复盘：健康元（600380）Q1净利降4.78%，股东户数减少2507户","url":"https://stock-news.laohu8.com/highlight/detail?id=2630807047","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630807047?lang=zh_cn&edition=full","pubTime":"2026-04-26 06:31","pubTimestamp":1777156268,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，健康元报收于10.83元，较上周的11.09元下跌2.34%。股本股东变化股东户数变动截至2026年3月31日，健康元股东户数为7.6万户，较2025年12月31日减少2507户，减幅3.19%。公司公告汇总健康元药业集团股份有限公司2026年第一季度报告健康元2026年第一季度实现营业收入3,721,497,528.96元，同比下降8.99%；利润总额1,036,837,891.56元，同比下降9.93%；归属于上市公司股东的净利润414,971,222.32元，同比下降4.78%；基本每股收益0.23元，与上年同期持平。原定任期至2027年8月27日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600004014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0114","BK0239","600380","BK0028","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630875040","title":"告别乙流多次服药！健康元创新药玛帕西沙韦胶囊或成更优选择","url":"https://stock-news.laohu8.com/highlight/detail?id=2630875040","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630875040?lang=zh_cn&edition=full","pubTime":"2026-04-25 08:24","pubTimestamp":1777076695,"startTime":"0","endTime":"0","summary":"近期，全国流感活动持续攀升，乙型流感强势主导本轮流行季，对公众健康构成显著威胁。中国疾控中心近期发布的全国急性呼吸道传染病哨点监测数据显示，全国流感病毒检测阳性率连续几周上升，北方省份检测阳性率高于南方。 目前，据了解玛帕西沙韦胶囊已在各大主流医药电商平台上线，患者可便捷咨询购买，有效提升了药品可及性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangjuejin/20260425/32173558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159992","BK1574","BK0114","BK1161","BK0046","BK0028","06978","BK0077","BK0188","BK0239","600380"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629842216","title":"健康元(600380.SH)发布一季度业绩，归母净利润4.15亿元，同比下降4.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629842216","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629842216?lang=zh_cn&edition=full","pubTime":"2026-04-24 21:39","pubTimestamp":1777037979,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健康元(600380.SH)披露2026年第一季度报告，报告期公司实现营收37.21亿元，同比下降8.99%;归母净利润4.15亿元，同比下降4.78%;扣非净利润4.06亿元，同比下降4.18%。基本每股收益0.23元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433743.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600380"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629511817","title":"图解健康元一季报：第一季度单季净利润同比下降4.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629511817","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629511817?lang=zh_cn&edition=full","pubTime":"2026-04-24 18:06","pubTimestamp":1777025186,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元2026年一季报显示，一季度公司主营收入37.21亿元，同比下降8.99%；归母净利润4.15亿元，同比下降4.78%；扣非净利润4.06亿元，同比下降4.18%；负债率30.86%，投资收益4903.07万元，财务费用-1421.08万元，毛利率63.19%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400054266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600380"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629281209","title":"健康元(600380)3月31日股东户数7.6万户，较上期减少3.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629281209","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629281209?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:52","pubTimestamp":1777024359,"startTime":"0","endTime":"0","summary":"证券之星消息，近日健康元披露，截至2026年3月31日公司股东户数为7.6万户，较12月31日减少2507.0户，减幅为3.19%。在化学制药行业个股中，健康元股东户数高于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.51万户。从股价来看，2025年12月31日至2026年3月31日，健康元区间跌幅为3.03%，在此期间股东户数减少2507.0户，减幅为3.19%。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/24/20260424643398.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/24/20260424643398.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260424/32172288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["600380","BK0028","BK0114","BK0077","BK0239","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626196517","title":"健康元最新公告：控股子公司JP-1366片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626196517","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626196517?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:49","pubTimestamp":1775814580,"startTime":"0","endTime":"0","summary":"健康元(600380.SH)公告称，公司控股子公司丽珠集团近日收到国家药监局核准签发的《药物临床试验批准通知书》，同意其申报的JP-1366片开展“与适当的抗生素联用以根除幽门螺杆菌”适应症的临床试验。JP-1366片是一款创新钾离子竞争性酸阻滞剂(P-CAB)，此前该药用于治疗反流性食管炎适应症的上市申请已获受理。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000031077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0028","BK0046","BK0188","600380","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625935060","title":"健康元(600380.SH)：TSLP单抗新增适应症获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2625935060","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625935060?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:02","pubTimestamp":1775552567,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健康元(600380.SH)发布公告，近日，公司收到国家药品监督管理局(简称：国家药监局)核准签发的关于公司的TSLP单抗新增“慢性鼻窦炎伴鼻息肉(CRSwNP)”适应症的《药物临床试验批准通知书》。JKN2401注射液(简称：本品)是一款靶向胸腺基质淋巴细胞生成素(TSLP)的创新生物制剂，拟用于呼吸系统及气道炎症相关疾病的治疗。TSLP是上皮源性关键细胞因子之一，位于多条炎症级联反应通路上游，在气道炎症及慢性鼻窦炎伴鼻息肉等疾病的发生和发展过程中发挥重要作用。通过靶向阻断TSLP通路，本品有望从炎症反应上游对疾病进程进行干预，从而改善相关症状并降低疾病复发风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"健康元(600380.SH)：TSLP单抗新增适应症获得药物临床试验批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0114","600380","BK0046","BK0188","BK0239","BK0077","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624651537","title":"健康元（600380）披露2025年年度报告，4月3日股价下跌1.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624651537","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624651537?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:08","pubTimestamp":1775210897,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，健康元报收于11.28元，较前一交易日下跌1.57%，最新总市值为206.36亿元。该股当日开盘11.4元，最高11.45元，最低11.25元，成交额达1.59亿元，换手率为0.76%。健康元药业集团股份有限公司于近日披露《2025年年度报告》。公告显示，截至2025年12月31日，母公司报表期末未分配利润为277,578.45万元。2025年公司总资产为35,414,299,308.64元，归属于上市公司股东的净资产为15,179,567,286.42元。经营活动产生的现金流量净额为3,891,842,483.63元，同比增长7.03%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300035081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","600380","BK0114","BK0188","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624059938","title":"健康元(600380)3月31日股东户数7.66万户，较上期减少2.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624059938","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624059938?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:12","pubTimestamp":1775034767,"startTime":"0","endTime":"0","summary":"证券之星消息，近日健康元披露，截至2026年3月31日公司股东户数为7.66万户，较12月31日减少1943.0户，减幅为2.47%。在化学制药行业个股中，健康元股东户数高于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.45万户。从股价来看，2025年12月31日至2026年3月31日，健康元区间跌幅为3.03%，在此期间股东户数减少1943.0户，减幅为2.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100031096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0188","BK0028","600380","BK0046","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623838615","title":"健康元(600380.SH)发布2025年度业绩，归母净利润13.36亿元，同比下降3.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623838615","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623838615?lang=zh_cn&edition=full","pubTime":"2026-03-31 18:56","pubTimestamp":1774954568,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健康元 披露2025年年度报告，报告期公司实现营收152.16亿元，同比下降2.58%;归母净利润13.36亿元，同比下降3.68%;扣非净利润13.07亿元，同比下降0.94%;基本每股收益0.73元。报告期，公司实现主营业务收入150.88亿元，较上年同期降低4.03亿元，同比下降2.60%。化学制剂实现营业收入72.86亿元，同比下降5.64%，化学原料药及中间体实现营业收入47.09亿元，同比下降5.76%。中药制剂实现营业收入16.86亿元，同比增长14.47%。诊断试剂及设备实现营业收入6.57亿元，同比下降8.56%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423109.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"健康元(600380.SH)发布2025年度业绩，归母净利润13.36亿元，同比下降3.68%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600380"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623338963","title":"每周股票复盘：健康元（600380）获两项药物临床试验批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2623338963","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623338963?lang=zh_cn&edition=full","pubTime":"2026-03-29 03:22","pubTimestamp":1774725732,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，健康元报收于10.98元，较上周的10.96元上涨0.18%。健康元药业集团股份有限公司控股子公司丽珠医药集团股份有限公司全资子公司珠海市丽珠微球科技有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意注射用布瑞哌唑微球开展用于成人精神分裂症的临床试验。后续仍需开展临床试验，上市存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","600380","BK0046","BK0188","BK0239","BK0077","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622685509","title":"健康元最新公告：新一代糖皮质激素获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622685509","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622685509?lang=zh_cn&edition=full","pubTime":"2026-03-26 18:01","pubTimestamp":1774519288,"startTime":"0","endTime":"0","summary":"健康元(600380.SH)公告称，公司收到国家药监局签发的《药物临床试验批准通知书》，同意其自主研发的新一代吸入用糖皮质激素JKN2404吸入混悬液(化学药品1类)开展用于支气管哮喘的临床试验。该药物为高选择性小分子ICS创新药，具有高局部抗炎效用和低全身毒副作用特征，有望降低传统ICS药物带来的HPA轴抑制及儿童生长迟缓等风险。截至公告日，该项目累计研发投入约2258.39万元。据IQVIA数据，2025年国内ICS类药物终端销售额约46.58亿元。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600033066.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0077","BK0114","600380","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622385508","title":"健康元最新公告：注射用布瑞哌唑微球获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2622385508","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622385508?lang=zh_cn&edition=full","pubTime":"2026-03-26 17:59","pubTimestamp":1774519197,"startTime":"0","endTime":"0","summary":"健康元(600380.SH)公告称，公司控股子公司丽珠集团全资子公司珠海市丽珠微球科技有限公司收到国家药监局签发的《药物临床试验批准通知书》，同意其申报的注射用布瑞哌唑微球开展用于成人精神分裂症的临床试验。该药品为化学药品2.2类改良型新药，系长效缓释微球制剂，拟定给药方式为每月一次肌肉注射，旨在提升患者用药依从性、降低复发风险。截至公告日，该药品累计研发投入约752.64万元。目前国内尚无布瑞哌唑长效制剂获批上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600033063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0077","BK0239","600380","BK0188","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621089909","title":"股市必读：健康元（600380）3月23日收盘跌5.2%，主力净流入601.31万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621089909","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621089909?lang=zh_cn&edition=full","pubTime":"2026-03-24 03:19","pubTimestamp":1774293589,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，健康元报收于10.39元，下跌5.2%，换手率1.16%，成交量21.18万手，成交额2.23亿元。当日关注点来自交易信息汇总：健康元股价连续4日下跌，累计跌幅达6.65%，主力资金前10个交易日累计净流出6268.19万元。交易信息汇总股价提醒3月23日健康元收盘报10.39元，跌5.2%，当日成交2118.08万元。资金流向3月23日主力资金净流入601.31万元，占总成交额2.7%；游资资金净流入938.24万元，占总成交额4.21%；散户资金净流出1539.55万元，占总成交额6.91%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400004154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0114","BK0046","BK0028","BK0239","600380","BK0077"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778876857266,"stockEarnings":[{"period":"1week","weight":-0.0251},{"period":"1month","weight":-0.0758},{"period":"3month","weight":-0.0806},{"period":"6month","weight":-0.174},{"period":"1year","weight":-0.0044},{"period":"ytd","weight":-0.0918}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.0131},{"period":"6month","weight":0.0363},{"period":"1year","weight":0.2232},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"健康元药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"76018人(较上一季度减少3.19%)","perCapita":"24066股","listingDate":"2001-06-08","address":"广东省深圳市南山区高新区北区朗山路17号健康元药业集团大厦","registeredCapital":"182945万元","survey":" 健康元药业集团股份有限公司的主营业务是医药产品及保健品研发、生产及销售。公司的主要产品是化学制剂、化学原料药及中间体、中药制剂、诊断试剂及设备、保健食品、生物制品。","listedPrice":24.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"健康元(600380)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供健康元(600380)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"健康元,600380,健康元股票,健康元股票老虎,健康元股票老虎国际,健康元行情,健康元股票行情,健康元股价,健康元股市,健康元股票价格,健康元股票交易,健康元股票购买,健康元股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"健康元(600380)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供健康元(600380)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}